Movement disorders with neuronal antibodies: Syndromic approach, genetic parallels and pathophysiology

Brain

Volumn 141, Issue 1, 2018, Pages 13-36

  Balint, Bettina ^a,b,c   Vincent, Angela ^c   Meinck, Hans Michael ^b   Irani, Sarosh R ^c   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

ataxia; chorea; movement disorders; neuronal antibodies; parkinsonism

Indexed keywords

AUTOANTIBODY; BRAIN ANTIBODY; CELL NUCLEUS ANTIGEN; DPYSL5 PROTEIN, HUMAN; NERVE PROTEIN;

ANTIGEN SPECIFICITY; CEREBELLAR ATAXIA; CHOREA; DEGENERATIVE DISEASE; DYSTONIA; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPEREKPLEXIA; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); MYOCLONUS; MYOKYMIA; NERVE DEGENERATION; NERVE EXCITABILITY; NONHUMAN; PARASOMNIA; PARKINSONISM; PAROXYSMAL KINESIGENIC DYSKINESIA; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PRIORITY JOURNAL; REVIEW; SPECTRUM; STIFF MAN SYNDROME; TAUOPATHY; TIC; TREMOR; GENETICS; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOLOGY;

AUTOANTIBODIES; HUMANS; MOVEMENT DISORDERS; NERVE TISSUE PROTEINS; NEURONS;

EID: 85040695510     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx189     Document Type: Review

References (144)

1. Abgrall G, Demeret S, Rohaut B, Leu-Semenescu S, Arnulf I. Status dissociatus and disturbed dreaming in a patient with Morvan syndrome plus Myasthenia Gravis. Sleep Med 2015; 16: 894-6.
2. Angus-Leppan H, Rudge P, Mead S, Collinge J, Vincent A. Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 2013; 70: 919-22.
3. Arino H, Gresa-Arribas N, Blanco Y, Martinez-Hernandez E, Sabater L, Petit-Pedrol M, et al. Cerebellar ataxia and glutamic acid decarb-oxylase antibodies: immunologic profile and long-term effect of im-munotherapy. JAMA Neurol 2014; 71: 1009-16.
4. Armangue T, Leypoldt F, Malaga I, Raspall-Chaure M, Marti I, Nichter C, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014a; 75: 317-23.
5. Armangue T, Sabater L, Torres-Vega E, Martinez-Hernandez E, Arino H, Petit-Pedrol M, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016; 73: 417-24.
6. Armangue T, Titulaer MJ, Sabater L, Pardo-Moreno J, Gresa-Arribas N, Barbero-Bordallo N, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014b; 75: 435-41.
7. Balint B, Bhatia K.P. Isolated and combined dystonia syndromes-an update on new genes and their phenotypes. Eur J Neurol 2015; 22: 610-17.
8. Balint B, Bhatia K.P. Stiff person syndrome and other immune-mediated movement disorders-new insights. Curr Opin Neurol 2016; 29: 496-506.
9. Balint B, Blöcker I, Unger M, Stoecker W, Probst C, Komorowski L, et al. Antibody spectrum in stiff person syndrome and related dis-orders. In: 19th International Congress of Parkinson's Disease and Movement Disorders, 2015. Wiley-Blackwell 111 River St, Hoboken 07030-5774, NJ USA; 2015. p. S263-S.
10. Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blocker IM, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 2014a; 82: 1521-8.
11. Balint B, Mahant N, Meinck HM, Fung V. Stiff limb syndrome mimicking corticobasal syndrome. Mov Disord Clin Pract 2014b; 1: 354-6.
12. Becker EB, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012; 83: 437-40.
13. Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135 (Pt 5): 1622-38.
14. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, et al. Encephalitis and antibodies to dipeptidyl-peptid-ase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013; 73: 120-8.
15. Boscolo S, Lorenzon A, Sblattero D, Florian F, Stebel M, Marzari R, et al. Anti transglutaminase antibodies cause ataxia in mice. PLoS One 2010; 5: e9698.
16. Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014; 137 (Pt 8): 2178-92.
17. Chang T, Alexopoulos H, McMenamin M, Carvajal-Gonzalez A, Alexander SK, Deacon R, et al. Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome. JAMA Neurol 2013; 70: 1140-9.
18. Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 2016; 530: 434-40.
19. Coesmans M, Smitt PA, Linden DJ, Shigemoto R, Hirano T, Yamakawa Y, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003; 53: 325-36.
20. Compta Y, Iranzo A, Santamaria J, Casamitjana R, Graus F. REM sleep behavior disorder and narcoleptic features in anti-Ma2-asso-ciated encephalitis. Sleep 2007; 30: 767-9.
21. Daggett A, Yang XW. Huntington's disease: easing the NMDAR traffic jam. Nat Med 2013; 19: 971-3.
22. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014; 76: 82-94.
23. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Eng J Med 2001; 345: 1870-6.
24. Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012; 135 (Pt 11): 3453-68.
25. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7: 1091-8.
26. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127 (Pt 8): 1831-44.
27. de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71: 815-24.
28. Doppler K, Schleyer B, Geis C, Grunewald B, Putz E, Villmann C, et al. Lockjaw in stiff-person syndrome with autoantibodies against glycine receptors. Neurol Neuroimmunol Neuroinflamm 2016; 3: e186.
29. Edwards MJ, Stamelou M, Quinn N, Bhatia K.P. Parkinson's disease and other movement disorders. Oxford, UK: Oxford University Press; 2016.
30. Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 2016; 73: 1297-307.
31. Finke C, Pruss H, Scheel M, Ostendorf F, Harms L, Borowski K, et al. Anti-NMDA receptor antibodies in a case of MELAS syndrome. J Neurol 2012; 259: 582-4.
32. Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 2017; 81: 298-309.
33. Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuro inflamm 2015; 2: e161.
34. Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas MC. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. J Neuroimmunol 2015; 281: 73-7.
35. Frisullo G, Della Marca G, Mirabella M, Caggiula M, Broccolini A, Rubino M, et al. A human anti-neuronal autoantibody against GABA B receptor induces experimental autoimmune agrypnia. Exp Neurol 2007; 204: 808-18.
36. Fujita K, Yuasa T, Takahashi Y, Tanaka K, Sako W, Koizumi H, et al. Antibodies to N-methyl-D-aspartate glutamate receptors in Creutzfeldt-Jakob disease patients. J Neuroimmunol 2012; 251: 90-3.
37. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012; 54: 899-904.
38. Gaig C, Graus F, Compta Y, Hogl B, Bataller L, Bruggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017; 88: 1736-43.
39. Geis C, Weishaupt A, Grunewald B, Wultsch T, Reif A, Gerlach M, et al. Human stiff-person syndrome IgG induces anxious behavior in rats. PLoS One 2011; 6: e16775.
40. Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, et al. Stiff person syndrome-associated autoantibodies to amphi-physin mediate reduced GABAergic inhibition. Brain 2010; 133: 3166-80.
41. Gelpi E, Hoftberger R, Graus F, Ling H, Holton JL, Dawson T, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016; 132: 531-43.
42. Geschwind MD, Tan KM, Lennon VA, Barajas RF Jr, Haman A, Klein CJ, et al. Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol 2008; 65: 1341-6.
43. Govert F, Witt K, Erro R, Hellriegel H, Paschen S, Martinez-Hernandez E, et al. Orthostatic myoclonus associated with Caspr2 antibodies. Neurology 2016; 86: 1353-5.
44. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404.
45. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol 2010; 69: 997-1007.
46. Gresa-Arribas N, Arino H, Martinez-Hernandez E, Petit-Pedrol M, Sabater L, Saiz A, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxyl-ase autoimmunity. PLoS One 2015; 10: e0121364.
47. Gresa-Arribas N, Planaguma J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, et al. Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology 2016; 86: 2235-42.
48. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167-77.
49. Hacohen Y, Dlamini N, Hedderly T, Hughes E, Woods M, Vincent A, et al. N-methyl-D-aspartate receptor antibody-associated movement disorder without encephalopathy. Dev Med Child Neurol 2014; 56: 190-3.
50. Hadjivassiliou M, Aeschlimann P, Sanders DS, Maki M, Kaukinen K, Grunewald RA, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology 2013; 80: 1740-5.
51. Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 2008; 64: 332-43.
52. Hampe CS, Petrosini L, De Bartolo P, Caporali P, Cutuli D, Laricchiuta D, et al. Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet J Rare Dis 2013; 8: 82.
53. Hegde M, Glass GA, Dalmau J, Christine CW. A case of slow ortho-static tremor, responsive to intravenous immunoglobulin. Mov Disord 2011; 26: 1563-5.
54. Hill KE, Clawson SA, Rose JW, Carlson NG, Greenlee JE. Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immu-notherapeutics. J Neuroinflammation 2009; 6: 31.
55. Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017; 32: 853-64.
56. Hutchinson M, Waters P, McHugh J, Gorman G, O'Riordan S, Connolly S, et al. Progressive encephalomyelitis, rigidity, and myo-clonus: a novel glycine receptor antibody. Neurology 2008; 71: 1291-2.
57. Irani S.R. 'Moonlighting' surface antigens: a paradigm for autoanti-body pathogenicity in neurology? Brain 2016; 139 (Pt 2): 304-6.
58. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leu-cine-rich, glioma inactivated 1 protein and contactin-associated pro-tein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-48.
59. Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 2014; 76: 168-84.
60. Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900.
61. Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72: 241-55.
62. Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of im-munotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013; 136 (Pt 10): 3151-62.
63. Iranzo A, Graus F, Clover L, Morera J, Bruna J, Vilar C, et al. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 2006; 59: 178-81.
64. Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neu-roprotective interventions. Lancet Neurol 2016; 15: 405-19.
65. Jain A, Balice-Gordon R. Cellular, synaptic, and circuit effects of anti-bodies in autoimmune CNS synaptopathies. Handb Clin Neurol 2016; 133: 77-93.
66. Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuro-myelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010; 7: 52.
67. Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, et al. GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol 2013; 256: 94-6.
68. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical char-acteristics. Arch Neurol 2012; 69: 1026-31.
69. Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 2012; 69: 1598-607.
70. Klein CJ, Lennon VA, Aston PA, McKeon A, O'Toole O, Quek A, et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 2013; 70: 229-34.
71. Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012; 79: 1136-44.
72. Krogias C, Hoepner R, Muller A, Schneider-Gold C, Schroder A, Gold R. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol 2013; 70: 1056-9.
73. Kunze A, Drescher R, Kaiser K, Freesmeyer M, Witte OW, Axer H. Serial FDG PET/CT in autoimmune encephalitis with faciobrachial dystonic seizures. Clin Nucl Med 2014; 39: e436-8.
74. Kurtis MM, Toledano R, Garcia-Morales I, Gil-Nagel A. Immunomodulated parkinsonism as a presenting symptom of LGI1 antibody encephalitis. Parkinsonism Relat Disord 2015; 21: 1286-7.
75. Labate A, Quattrone A, Dalmau J, Gambardella A. Anti-N-methyl-D-aspartate-glutamic-receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. Mov Disord 2013; 28: 820-2.
76. Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8: 380-90.
77. Lancaster E, Leypoldt F, Titulaer MJ, Honnorat J, Waters PJ, Reindl M, et al. Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol 2015; 77: 183.
78. Lemke JR, Geider K, Helbig KL, Heyne HO, Schutz H, Hentschel J, et al. Delineating the GRIN1 phenotypic spectrum: a distinct genetic NMDA receptor encephalopathy. Neurology 2016; 86: 2171-8.
79. Leypoldt F, Hoftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, et al. Investigations on CXCL13 in anti-N-methyl-D-aspar-tate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol 2015; 72: 180-6.
80. Lindfors K, Koskinen O, Laurila K, Collin P, Saavalainen P, Haimila K, et al. IgA-class autoantibodies against neuronal transglutaminase, TG6 in celiac disease: no evidence for gluten dependency. Clin Chim Acta 2011; 412: 1187-90.
81. Mackay G, Ahmad K, Stone J, Sudlow C, Summers D, Knight R, et al. NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol 2012; 259: 1979-81.
82. Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor en-cephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis 2010; 5: 31.
83. Martin-Garcia E, Mannara F, Gutierrez-Cuesta J, Sabater L, Dalmau J, Maldonado R, et al. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013; 261: 53-9.
84. Manto MU, Hampe CS, Rogemond V, Honnorat J. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis 2011; 6: 3.
85. Martinez-Hernandez E, Arino H, McKeon A, Iizuka T, Titulaer MJ, Simabukuro MM, et al. Clinical and immunologic investigations in patients with stiff-person spectrum disorder. JAMA Neurol 2016; 73: 714-20.
86. McKasson M, Clardy SL, Clawson SA, Hill KE, Wood B, Carlson N, et al. Voltage-gated calcium channel autoimmune cerebellar degeneration: Case and study of cytotoxicity. Neurol Neuroimmunol Neuroinflamm 2016; 3: e222.
87. McKeon A, Ahlskog JE, Britton JW, Lennon VA, Pittock SJ. Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol 2009; 66: 268-71.
88. McKeon A, Lennon VA, Pittock SJ, Kryzer TJ, Murray J. The neurologic significance of celiac disease biomarkers. Neurology 2014; 83: 1789-96.
89. McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013; 70: 44-50.
90. McKeon A, Pittock SJ, Glass GA, Josephs KA, Bower JH, Lennon VA, et al. Whole-body tremulousness: isolated generalized polymyoclo-nus. Arch Neurol 2007; 64: 1318-22.
91. Meinck HM, Faber L, Morgenthaler N, Seissler J, Maile S, Butler M, et al. Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J Neurol Neurosurg Psychiatry 2001; 71: 100-3.
92. Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 2012; 135 (Pt 5): 1606-21.
93. Mohammad SS, Fung VS, Grattan-Smith P, Gill D, Pillai S, Ramanathan S, et al. Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord 2014a; 29: 1539-42.
94. Mohammad SS, Sinclair K, Pillai S, Merheb V, Aumann TD, Gill D, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord 2014b; 29: 117-22.
95. Morris-Berry CM, Pollard M, Gao S, Thompson C, Singer HS. Anti-streptococcal, tubulin, and dopamine receptor 2 antibodies in children with PANDAS and Tourette syndrome: single-point and longi-tudinal assessments. J Neuroimmunol 2013; 264: 106-13.
96. Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 76: 108-19.
97. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71: 1955-8.
98. Naasan G, Irani SR, Bettcher BM, Geschwind MD, Gelfand JM. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 2014; 71: 1300-4.
99. Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N, Takashima H, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33: 18161-74.
100. O'Toole O, Lennon VA, Ahlskog JE, Matsumoto JY, Pittock SJ, Bower J, et al. Autoimmune chorea in adults. Neurology 2013; 80: 1133-44.
101. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-7.
102. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276-86.
103. Pettingill P, Kramer HB, Coebergh JA, Pettingill R, Maxwell S, Nibber A, et al. Antibodies to GABAA receptor alpha1 and gamma2 sub-units: clinical and serologic characterization. Neurology 2015; 84: 1233-41.
104. Piepgras J, Holtje M, Michel K, Li Q, Otto C, Drenckhahn C, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology 2015; 85: 890-7.
105. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear auto-antibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53: 580-7.
106. Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchinetti CF, Tan KM, et al. Paraneoplastic jaw dystonia and laryngospasm with antineur-onal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 2010; 67: 1109-15.
107. Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, et al. Glutamic acid decarboxylase autoimmunity with brain-stem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81: 1207-14.
108. Planagumà J, Haselmann H, Mannara F, Petit-Pedrol M, Grünewald B, Aguilar E, et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. Ann Neurol 2016; 80: 388-400.
109. Planaguma J, Leypoldt F, Mannara F, Gutierrez-Cuesta J, Martin-Garcia E, Aguilar E, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015; 138 (Pt 1): 94-109.
110. Provini F, Marconi S, Amadori M, Guaraldi P, Pierangeli G, Cortelli P, et al. Morvan chorea and agrypnia excitata: when video-poly-somnographic recording guides the diagnosis. Sleep Med 2011; 12: 1041-3.
111. Pruss H, Finke C, Holtje M, Hofmann J, Klingbeil C, Probst C, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex ence-phalitis. Ann Neurol 2012a; 72: 902-11.
112. Pruss H, Holtje M, Maier N, Gomez A, Buchert R, Harms L, et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012b; 78: 1743-53.
113. Ramaekers VT, Rothenberg SP, Sequeira JM, Opladen T, Blau N, Quadros EV, et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med 2005; 352: 1985-91.
114. Ramakrishnan S. Human ephrin-like receptor. Google Patents, 2003. http://google.com/patents/WO2001072833A3?cl=en
115. Rubio-Agusti I, Dalmau J, Sevilla T, Burgal M, Beltran E, Bataller L. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord 2011; 26: 351-2.
116. Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and postmortem study. Lancet Neurol 2014; 13: 575-86.
117. Sabater L, Planaguma J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 2016; 13: 226.
118. Sanz R, Ferraro GB, Fournier AE. IgLON cell adhesion molecules are shed from the cell surface of cortical neurons to promote neuronal growth. J Biol Chem 2015; 290: 4330-42.
119. + ATPase is an autoantibody target in para-neoplastic neurologic syndrome. Neurology 2015; 84: 1673-9.
120. Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126 (Pt 6): 1409-18.
121. Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoanti-bodies against a glutamate receptor. N Engl J Med 2000; 342: 21-7.
122. Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365: 1406-11.
123. Stamelou M, Plazzi G, Lugaresi E, Edwards MJ, Bhatia K.P. The distinct movement disorder in anti-NMDA receptor encephalitis may be related to status dissociatus: a hypothesis. Mov Disord 2012; 27: 1360-3.
124. Stamelou M, Quinn NP, Bhatia K.P. "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supra-nuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Mov Disord 2013; 28: 1184-99.
125. Standaert DG, Testa CM, Young AB, Penney JB Jr. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol 1994; 343: 1-16.
126. Stenberg R, Hadjivassiliou M, Aeschlimann P, Hoggard N, Aeschlimann D. Anti-transglutaminase 6 antibodies in children and young adults with cerebral palsy. Autoimmune Dis 2014; 2014: 237107.
127. Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011; 77: 269-75.
128. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spec-trum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70: 1883-90.
129. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-65.
130. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83: 1797-803.
131. Tofaris GK, Irani SR, Cheeran BJ, Baker IW, Cader ZM, Vincent A. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012; 79: 195-6.
132. Tomimitsu H, Arimura K, Nagado T, Watanabe O, Otsuka R, Kurono A, et al. Mechanism of action of voltage-gated K + channel antibodies in acquired neuromyotonia. Ann Neurol 2004; 56: 440-4.
133. Tuzun E, Erdag E, Durmus H, Brenner T, Turkoglu R, Kurtuncu M, et al. Autoantibodies to neuronal surface antigens in thyroid anti-body-positive and-negative limbic encephalitis. Neurol India 2011; 59: 47-50.
134. Udani V, Desai N, Botre A. Partial manifestation of anti-NMDA-R encephalitis with predominant movement disorder. Mov Disord Clin Pract 2016; 3: 80-2.
135. Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol 2013; 23: 684-95.
136. Vigliani MC, Honnorat J, Antoine JC, Vitaliani R, Giometto B, Psimaras D, et al. Chorea and related movement disorders of para-neoplastic origin: the PNS EuroNetwork experience. J Neurol 2011; 258: 2058-68.
137. Vitali P, Maccagnano E, Caverzasi E, Henry RG, Haman A, Torres-Chae C, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 2011; 76: 1711-19.
138. Wang JL, Yang X, Xia K, Hu ZM, Weng L, Jin X, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 2010; 133 (Pt 12): 3510-18.
139. Werner C, Pauli M, Doose S, Weishaupt A, Haselmann H, Grunewald B, et al. Human autoantibodies to amphiphysin induce defective presynap-tic vesicle dynamics and composition. Brain 2016; 139 (Pt 2): 365-79.
140. Witherick J, Highley JR, Hadjivassiliou M. Pathological findings in a case of stiff person syndrome with anti-GAD antibodies. Mov Disord 2011; 26: 2138-9.
141. Xia C, Dubeau F. Teaching video NeuroImages: dystonic posturing in anti-NMDA receptor encephalitis. Neurology 2011; 76: e80.
142. Yap SM, Lynch T, MacMahon P, Murray B. Paraneoplastic atypical parkinsonism with anti-CRMP5 antibodies and severe caudate and putaminal hypometabolism on 18-fluorodeoxyglucose positron emission tomography of the brain. Mov Disord Clin Pract 2017; 4: 263-5.
143. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thym-oma-related autoimmunity. Ann Neurol 2001; 49: 146-54.
144. Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993; 43: 414-17.